SUBSCRIBE
SUBSCRIBE

Phase 1

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
CAR-T Cell Companies Juno Therapeutics, Kite Pharma, and ZIOPHARM, Inc. Get Stock Jitters on Disappointing Novartis AG Trial News
April 21, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Merck & Co.'s Keytruda Effective Against Three Cancers
April 20, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
AstraZeneca PLC’s Experimental Lung Cancer Drug Delays Disease By More Than a Year
April 17, 2015
 · 
2 min read
Drug Development
Targacept Abandons Nictoine Focus for Alzheimer’s
April 6, 2015
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
New Research Throws Cold Water on Biogen’s Recent Breakthrough
March 24, 2015
 · 
5 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Drug Development
Eli Lilly,Novartis AG-Backed Startup, Aeglea, Nabs $44 Million
March 23, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Drug Development
Biogen Drops Idec From Corporate Name, Expands Ambitions in Alzheimer’s, ALS
March 23, 2015
 · 
2 min read
Analysts Not Sold On Medivation’s Xtandi as Breast Cancer Drug
Drug Development
Biogen Slides For Alzheimer’s Drug Wow Analysts, Set Up Fight for Eli Lilly
March 20, 2015
 · 
4 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Prothena Soars on Positive Phase I Results Of Parkinson’s Drug PRX002
March 20, 2015
 · 
2 min read
ISIS Pharmaceuticals Inks $155M Bayer Deal Just After Good News From Biogen Collaboration
Business
Another Day, Another $456 Million Cancer Pact for Eli Lilly
March 20, 2015
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Aramis Biotechnologies announces the achievement of an important milestone with the start of a Phase 1/2 clinical trial of its vaccine in development against seasonal influenza in 728 participants
February 26, 2026
 · 
2 min read
Press Releases
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
February 26, 2026
 · 
7 min read
Press Releases
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
February 26, 2026
 · 
3 min read
Press Releases
Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership
February 26, 2026
 · 
5 min read
Press Releases
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
February 26, 2026
 · 
7 min read
Press Releases
Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds
February 26, 2026
 · 
2 min read
Press Releases
Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase 1 Clinical Trial
February 26, 2026
 · 
3 min read
Press Releases
Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome
February 26, 2026
 · 
4 min read
Press Releases
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
February 25, 2026
 · 
11 min read
Press Releases
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
February 25, 2026
 · 
5 min read
Press Releases
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
February 25, 2026
 · 
8 min read
Press Releases
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026
 · 
7 min read
Press Releases
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
February 25, 2026
 · 
6 min read
Press Releases
Vico Therapeutics Announces Patient Dosing in Twice-Annual Regimen of VO659 in Phase 1/2 Trial in Huntington’s Disease, Spinocerebellar Ataxia Type 3 and Type 1
February 24, 2026
 · 
3 min read
Press Releases
Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer
February 24, 2026
 · 
4 min read
Press Releases
AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics’ Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
February 24, 2026
 · 
4 min read
Press Releases
Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
February 24, 2026
 · 
4 min read
Press Releases
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
February 24, 2026
 · 
10 min read
Press Releases
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
February 24, 2026
 · 
6 min read
Press Releases
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
February 24, 2026
 · 
11 min read
Load More